Ülkü YILMAZ, Nilgün YILMAZ DEMİRCİ, Funda DEMİRAĞ, Aydın YILMAZ, Yurdanur ERDOĞAN

EGFR, KRAS, and BRAF mutational profiles of female patients with micropapillary predominant invasive lung adenocarcinoma

Background/aim: This study aimed to analyze EGFR, KRAS, and BRAF mutations in females with micropapillary predominant invasive lung adenocarcinoma and their relationships with immunohistochemical and clinicopathological patterns. Materials and methods: A total of 15 females with micropapillary lung adenocarcinoma were selected. Mutational analysis of the EGFR, KRAS, and BRAF genes was carried out. Information regarding the demographic data, tumor size, treatment, and survival time for each patient was collated, and the predominant cell type, secondary architectural growth patterns, psammoma bodies, necrosis, and visceral pleural and angiolymphatic invasions were evaluated. Results: We identified EGFR mutation in six cases, KRAS mutation in three cases, and BRAF mutation in one case. EGFR, c-kit, VEGFR, and bcl-2 positivity was observed in ten, seven, four, and six cases, respectively. All cases were positive for VEGF (strong positivity in 11 cases and weak positivity in four cases) and bcl-2 (strong positivity in nine cases and weak positivity in six cases). Seven (46.6%) cases were positive for c-kit and 10 (66.6%) cases were positive for EGFR. Conclusion: EGFR mutation occurred at a higher incidence rate in micropapillary predominant invasive adenocarcinoma than has previously been found in conventional lung adenocarcinomas. KRAS mutation was observed as having a similar frequency to what was previously observed, but the frequency of BRAF mutation was lower than previously reported.

PDF

___

1. Siegel R, Naishadham D, Jemal A. Cancer Statistics. CA-Cancer J Clin 2012; 62: 10-29.
2. Kerr KM. Pulmonary adenocarcinomas: classification and reporting. Histopathology 2009; 54: 12-27.
3. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger K, Yatabe Y, Beer DG, Powell CA, Riely GJ, Yan Schil PE et al. International Association for the Study of Lung Cancer/ American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. J Thorac Oncol 2011; 6: 244-285.
4. Tsutsumida H, Nomoto M, Goto M, Kitajima S, Kubota I, Hirotsu Y, Wakimoto J, Hollingsworth MA, Yonezawa S. A micropapillary pattern is predictive of a poor prognosis in lung adenocarcinoma, and reduced surfactant tapoprotein A expression in the micropapillary pattern is an excellent indicator of a poor prognosis. Modern Pathol 2007; 20: 638- 647.
5. Reungwetwattana T, Weroha SJ, Molina JR. Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC). Clin Lung Cancer 2012; 13: 252-266.
6. Achcar ROD, Nikforova MN, Yousem SA. Micropapillary lung adenocarcinoma, EGFR, K-ras, and BRAF mutational profile. Am J Clin Pathol 2009; 131: 694-700.
7. Zhang J, Liang Z, Gao J, Luo Y, Liu T. Pulmonary adenocarcinoma with a micropapillary pattern: a clinicopathological, immunophenotypic and molecular analysis. Histopathology 2011; 59: 1204-1214.
8. Ohe M, Yokose T, Sakuma Y, Miyagi Y, Okamoto N, Osanai S, Hasegawa C, Nakayama H, Kameda Y, Yamada K et al. Stromal micropapillary component as a novel unfavorable prognostic factor of lung adenocarcinoma. Diagn Pathol 2012; 7: 3.
9. Motoi N, Szoke J, Riely GJ, Seshan WE, Kris MG, Rusch VW, Gerald WL, Trawis WD. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol 2008; 32: 810-827.
10. Li H, Pan Y, Li Y, Li C, Wang R, Hu H, Zhang Y, Ye T, Wang L, Shen L et al. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose. Lung Cancer 2013; 79: 8-13.
11. Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest 2009; 136: 260-271.
12. Törmӓnen-Nӓpӓnkangas U, Soini Y, Kahlos K, Kinnula V, Pӓӓkkö P. Expression of caspases-3, -6 and -8 and their relation to apoptosis in non-small cell lung carcinoma. Int J Cancer 2001; 93: 192-198.
13. Amin MB, Tamboli P, Merchant SH, Ordonez NG, Ro J, Ayala AG, Ro JY. Micropapillary component in lung adenocarcinoma. A distinctive histologic feature with possible prognostic significance. Am J Surg Pathol 2002; 26: 358-364.
14. Kuroda N, Hamaguchi N, Takeuchi E, Ohara M, Hirouchi T, Mizuno K. Lung adenocarcinoma with micropapillary pattern: a clinicopathological study of 25 cases. APMIS 2006; 114: 381- 385.
15. Kamiya K, Hayashi Y, Douguchi J, Hashiguchi A, Yamada T, Izumi Y, Watanabe M, Kawamura M, Horinouchi H, Shimada N et al. Histopathological features and prognostic significance of the micropapillary pattern in lung adenocarcinoma. Mod Pathol 2008;21: 992-1001.
16. World Health Organization. Pathology and Genetics of Tumours of the Lung, Pleura and Heart. Lyon, France: IARC Press; 2004.
17. Ninomiya H, Hiramatsu M, Inamura K, Nomura K, Okui M, Miyoshi T, Okumuro S, Satoh Y, Nakagawa K, Nishio M et al. Correlation between morphology and EGFR mutations in lung adenocarcinomas: significance of the micropapillary pattern and the hobnail cell type. Lung Cancer 2009; 63: 235-240.
18. An SJ, Chen ZH, Su J, Zhang XC, Zhong WZ, Yang JJ, Zhou Q, Yang XN, Huang L, Guan JL et al. Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status. PLoS One 2012; 7: 1-8.
19. Finberg KE, Sequist LV, Joshi VA, Muzikansky A, Miller JM, Han M, Behesthi J, Chirieac LR, Mark EJ, Iafrate AJ. Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features. J Mol Diagn 2007; 9: 320-326.
20. Sun Y, Yu X, Shi X, Hong W, Zhao J, Shi L. Correlation of survival and EGFR mutation with predominant histologic subtype according to the new lung adenocarcinoma classification in stage IB patients. World J Surg Oncol 2014; 12: 148.
21. Zhang Y, Wang R, Cai D, Li Y, Pan Y, Hu H, Wang L, Li H, Ye T, Luo X et al. A comprehensive investigation of molecular features and prognosis of lung adenocarcinoma with micropapillary component. J Thorac Oncol 2014; 9: 1772-1778.
22. Mountzios G, Dimopoulos MA, Soria JC, Sanoudou D, Papadimitriou CA. Histopathologic and genetic alterations as predictors of response to treatment and survival in lung cancer: a review of published data. Crit Rev Oncol Hemat 2010; 75: 95- 109.
23. Yilmaz A, Ernam D, Unsal E, Demirag F, Atikcan Ş, Taştepe I. Vascular endothelial growth factor immunostaining correlates with postoperative relapse and survival in nonsmall cell lung cancer. Arch Med Res 2007; 38: 764-768.
24. Butnor KJ, Burchette JL, Sporn TA, Hammar SP, Roggli VL. The spectrum of kit (CD117) immunoreactivity in lung and pleural tumors. Arch Pathol Lab Med 2004; 128: 538-543.